BTIG analyst Thomas Shrader maintained a Buy rating on Coya Therapeutics, Inc. (COYA – Research Report) yesterday and set a price target of $15.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Thomas Shrader has given his Buy rating due to a combination of factors that highlight the potential of Coya Therapeutics, Inc. The company’s COYA-302 treatment has shown promising results in maintaining cognitive stability in symptomatic FTD patients, which is significant given the usual decline expected in such conditions. This stability is supported by the treatment’s dual approach using proven anti-inflammatory biologicals, which are also biosimilars, making manufacturing and quality control more straightforward.
Additionally, the potential applicability of COYA-302 to other related conditions like ALS, and the ongoing discussions with the FDA regarding future trials, add to the optimism. The company’s pipeline, particularly the COYA-303 program, which combines low dose IL2 with a GLP-1 receptor agonist, is also generating interest due to its potential in treating AD, a disease linked to inflammation and glucose levels. These factors combined suggest a promising outlook for Coya Therapeutics, justifying the Buy rating.
COYA’s price has also changed moderately for the past six months – from $9.910 to $6.530, which is a -34.11% drop .